Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families. The Company is focused on developing, manufacturing and commercializing specialty CNS pharmaceuticals for our own pipeline. Corium's lead product, CorplexTM Donepezil, is a once-weekly transdermal patch containing the active ingredient in Aricept for the treatment of patients with mild, moderate and severe Alzheimer’s disease. The Company's transdermal technologies enable the development of innovative new products through the simple, safe and efficient delivery of both small and large molecule therapeutics, which provides significant clinical and commercial advantages, including valuable product lifecycle management.

Menlo Park, US
Size (employees)
213 (est)
Corium International was founded in 1999 and is headquartered in Menlo Park, US
Report incorrect company information

Key People/Management at Corium International

Peter Staple

Peter Staple

President and Chief Executive Officer
Christina Dickerson

Christina Dickerson

Vice President of Corporate Development

Corium International Office Locations

Corium International has offices in Menlo Park and Kentwood
Menlo Park, US (HQ)
235 Constitution Dr
Kentwood, US
4558 50th St SE
Show all (2)
Report incorrect company information

Corium International Financials and Metrics

Corium International Financials

Corium International's revenue was reported to be $31.86 m in FY, 2017

Revenue (FY, 2017)

31.9 m

EBIT (FY, 2017)

(39.8 m)

Market capitalization (18-Apr-2018)

386.6 m

Cash (30-Sep-2017)

57.5 m


368.2 m
Corium International's current market capitalization is $386.6 m.
USDFY, 2017


31.9 m

General and administrative expense

13.2 m

R&D expense

31.9 m

Operating expense total

71.6 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


10.6 m7.5 m7 m10.6 m7 m7.3 m8.1 m

General and administrative expense

2.8 m3 m3 m3.1 m3 m3 m3.3 m

R&D expense

3.5 m4.5 m5.6 m5.5 m6 m7.5 m9.1 m

Operating expense total

14.6 m15 m15.5 m16.2 m15.4 m16.4 m19.5 m
USDFY, 2014FY, 2015FY, 2016FY, 2017


36.4 m72.2 m39.8 m57.5 m

Accounts Receivable

4.2 m4.5 m4.3 m4.6 m


1.3 m1.4 m2.4 m2.3 m

Current Assets

45.8 m81.8 m48.3 m65.6 m
USDFY, 2014FY, 2015FY, 2016FY, 2017


(255 k)(75 k)478 k124 k

Accounts Payable

700 k1.4 m(1.2 m)1.4 m

Cash From Operating Activities

(11.4 m)(20.7 m)(29.1 m)(37.2 m)

Purchases of PP&E

(3.2 m)(973 k)(1.4 m)(2.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Depreciation and Amortization

141 k159 k162 k168 k177 k178 k


1.9 m2.7 m

Accounts Payable

1.8 m2.6 m3.4 m2.6 m3.6 m2.7 m3.4 m3.1 m3.8 m3.7 m5.4 m
USDY, 2017


-9.3 x


-9.9 x


150.3 k

Financial Leverage

5.2 x
Show all financial metrics
Report incorrect company information